Drugmakers make serious profits on public procurements of anti-COVID-19 drugs in Russia

The Russian drugmaker R-Pharm topped the rating of pharmaceutical manufacturers in Russia that made the biggest profits from public procurements of anti-COVID-19 drugs by the state for first 10 months of the current year, according to a recent study conducted by DSM Group, one of Russia’s leading analyst agencies in the field of pharmaceuticals, reports The Pharma Letter’s local correspondent.

According to the study, the company generated almost 25 billion roubles ($340 million) during public procurements, which accounts for 25% of all funds spent by the state on purchases of anti-COVID-19 drugs this year. There are 28 international non-proprietary names (INN) included in the guidelines for the prevention and treatment of COVID-19, dated of October 14, 2021.

For 10 months of 2021, the value of such procurements increased 6.5-fold compared to the same period last year, amounting to 95.8 billion roubles in total. Three quarters of these funds were distributed among 10 pharmaceutical companies. In addition to R-Pharm (26%), among the leaders were Biocad (8.6%), Pfizer (NYSE: PFE) (6.6%), Bayer (BAYN: DE) (6.4%), Promomed Rus (5.4%), Roche (ROG: SIX) (5.2%), Aspen Pharma (4.4%), and Pharmasyntez (4.3%).